Il-23: Long-Term Data And Safety Data

IL-23: Long-term Data and Safety Data

Selecting from IL-23s

skinexpertstalk

Positioning anti-IL-12 and anti-IL-23 inhibitors

Advances in Anti-Cytokine Therapy: New Pathways (IL 12/23, IL17, IL23)

ClevelandClinicCME

Safety and Efficacy of IL-23 Inhibitors in Plaque Psoriasis

Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab

Annals of the Rheumatic Diseases

Long-term persistence and effectiveness of IL-12/23 pathway inhibitor ustekinumab and TNF inhibitors

Annals of the Rheumatic Diseases

IL-23 Inhibitors and Other Emerging Psoriasis Treatments

ClevelandClinicCME

Laura K. Ferris, MD, PhD - Do IL-17 inhibitors work more quickly than IL-23 inhibitors and what...

Use of IL-23 Inhibitors to Treat Plaque Psoriasis

Efficacy of IL-23 Inhibitors in Plaque Psoriasis

Biologics Targeting the IL-23/IL-17 Pathway in Psoriatic Disease: Treating Beyond the Skin

New Data Demonstrates Potential for Oral IL-23 in Psoriasis

HPR

IL23 & IL12/23 Inhibitors: An Overview

AlbertaRheumatology

WCH23: IL-17 vs IL-23 Blockers – Why and When?

IBD: Safety and Positioning of IL-23 Inhibitors Under Investigation

IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis

New Biologic Therapies that Target the IL-12/23 Pathway

Hitting the Target with IL-23 Inhibitors in Psoriatic Arthritis

Safety of biologics for the treatment of psoriasis

Dermatology Education